Business
Tata Motors, Maruti, Ashok Leyland, Hero: In Auto Stocks Rally, Optimism Over PM Modi’s GST Move
Last Updated:
Shares of auto majors, including Hero MotoCorp, Maruti Suzuki India, Ashok Leyland, TVS Motor and Bajaj Auto, rally 5-8% amid expectations of a GST rate cut.
Tata Motors rose nearly 3% on Monday.
The domestic equity market surged on Monday following Prime Minister Narendra Modi’s announcement on GST reforms, S&P Global’s rating upgrade on India, and other positive global cues. While the benchmark indices, the BSE Sensex and the NSE Nifty, are up by over 1.3% each, the automobile stocks are fuelling the rally the most, with the Nifty Auto Index trading higher by an impressive 4.5%.
Shares of auto majors, including Hero MotoCorp, Maruti Suzuki India, Ashok Leyland, TVS Motor and Bajaj Auto, rallied 5-8% on Monday morning amid expectations that the GST rate on vehicles could be reduced from 28% to 18%.
Maruti Suzuki on August 18 hit its all-time high of Rs 14,048 apiece on the NSE, which is up nearly 8.7% compared with the previous close. Ashok Leyland was up by 7.7% at Rs 131.25, Hero MotoCorp was trading higher by 6.7% at Rs 5,024, TVS Motor Company rose 6.8% to Rs 3,226.8, Hyundai Motor India surged by 8.39% to Rs 2,428 apiece on the NSE.
Tata Motors also rose nearly 3% on Monday to Rs 685 in morning, while Mahindra & Mahindra was up by 4.5% at Rs 3,412. Bajaj Auto was trading higher by 3.7% at Rs 8,521.
Prime Minister Narendra Modi in his Independence Day Speech during the weekend announced a major overhaul in the Goods and Services Tax (GST) structure. Though he did not announce any details, reports said the Centre is considering scrapping the current 12% and 28% GST slabs, realigning most items into the 5% and 18% categories. Certain sin or luxury goods may be placed in a new 40% bracket.
The Centre is reportedly expected to lower the GST on passenger vehicles (PVs) and two-wheelers, enhancing their affordability quotient. Currently, two-wheelers are taxed at 28%. Analysts believe a cut to 18% is highly probable.
Brokerage Notes
Global brokerage firm Jefferies in its note said, “All the listed 2W OEMs – Bajaj, Hero, TVS, and Eicher – should benefit from this cut. We see a low probability of differential GST between entry-level and premium 2Ws.”
In passenger vehicles, small cars currently face an effective tax of 29-31% including compensation cess, making Maruti Suzuki one of the biggest potential beneficiaries of a rate cut. SUVs, however, are taxed at 45-50%, a rate Jefferies said is unlikely to change.
“Hybrid vehicles attract a similar GST rate as ICE vehicles, compared with 5% for EVs. Any reduction in GST on hybrids could be positive for Maruti,” the brokerage added.
Commercial vehicles, also taxed at 28%, may see a reduction to 18%. Ashok Leyland, along with Tata Motors and Eicher Motors, would be key gainers in such a scenario, Jefferies said.
Domestic brokerage firm Motilal Oswal Financial Services in its report on August 18 said automobiles will be one of the key segments that stand to benefit from GST rationalisation.
Passenger vehicle makers Maruti Suzuki and Tata Motors, currently paying 28% GST, are expected to benefit significantly if rates are lowered to 18%. Commercial vehicle maker Ashok Leyland may also see demand tailwinds as GST on trucks and buses comes down to 18% from the current 28%, said Motilal Oswal in the report.
Arun Agarwal, vice-president (fundamental research) of Kotak Securities, said, “The potential GST cuts for the automotive products to 18% would lower on-road prices across segments. We believe lower prices would stimulate demand recovery, and the impact would be more in the mass-market segment. Auto manufacturers (OEM) would gain from higher revenue and potentially higher margin, resulting in possible earnings upgrade.”
Auto ancillaries would also gain from the potential GST cut. However, the impact would vary depending on geographical exposure. Auto ancillary companies having higher revenue exposure in the domestic market stands to benefit more, whereas the gains for global suppliers would be lower given higher export exposure and tariff-related uncertainty, he added.
The government is reportedly planning to propose a simplified two-slab GST structure of 5% and 18%, replacing the current four-tier system of 5%, 12%, 18% and 28%.

Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h…Read More
Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h… Read More
view comments
Read More
Business
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.
The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs.
Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes.
Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients.
Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx.
But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval.
That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly.
“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.
With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024.
It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound.
Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic.
The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment.
Business
OBR chairman resigns over Budget leak
The chairman of the Office for Budget Responsibility (OBR) has resigned over the early publication of the watchdog’s forecasts.
Richard Hughes said he was resigning to allow the OBR to “quickly move on from this regrettable incident”.
His resignation follows publication of a report that described the leak as “the worst failure in the 15-year history of the OBR” and strongly criticised the watchdog’s processes for protecting sensitive information.
In a letter to the Chancellor and the chairwoman of the Commons Treasury Committee, Mr Hughes said he took “full responsibility” for “the shortcomings identified in the report”.
He said: “By implementing the recommendations in this report, I am certain the OBR can quickly regain and restore the confidence and esteem that it has earned through 15 years of rigorous, independent economic analysis.”
Mr Hughes has served as chairman of the OBR since 2020 and was reappointed to the job for a second five-year term in July this year.
Speaking in the Commons as the news of the resignation broke, Chief Secretary to the Treasury James Murray offered the Government’s thanks to Mr Hughes “for his dedication to public service”.
Later, the Chancellor herself offered her thanks for Mr Hughes’ “many years of public service”, adding: “This Government is committed to protecting the independence of the OBR and the integrity of our fiscal framework and institutions.”
Conservative leader Kemi Badenoch accused the Chancellor of using Mr Hughes as a “human shield” and called on Rachel Reeves to resign.
Liberal Democrat Treasury spokeswoman Daisy Cooper said Mr Hughes was “a dedicated public servant” who had “rightly taken responsibility for a failure on his watch”, adding the OBR needed to learn from its “catastrophic error”.
Treasury Committee chairwoman Dame Meg Hillier also thanked Mr Hughes, saying: “I commend his decision to take full responsibility for the incident and I wish him well for the future.”
The Treasury said it would begin the process of finding a replacement for Mr Hughes “in the coming weeks”.
The OBR launched an investigation after official forecasts were uploaded to the watchdog’s website, releasing details of the Budget almost an hour early.
In a report published on Monday, the OBR said the leak had been “seriously disruptive to the Chancellor, who had every right to expect that the (forecasts) would not be publicly available until she sat down at the end of her Budget speech”.
Noting Mr Hughes had already “rightly” apologised for the leak, the report said it was “not a case of intentional leakage” or a matter of pressing publish too early.
The OBR said it was caused by two errors linked to the WordPress publishing site it used.
The report into the incident said that, while it knew web addresses for its files follow a pattern, it assumed “the protections provided” by WordPress “would ensure it could not be accessed”.
But two configuration errors were the technical causes of the premature access.
The forecast for the last spring statement in March was also “accessed prematurely” on one occasion, the report noted, but concluded that no activity appeared to have been taken as a result and the most likely explanation is “benign”.
The report recommended a review of the watchdog’s processes for publishing such documents.
“To rebuild trust, the leadership of the OBR must take immediate steps to change completely the publication arrangements for the two important and time-sensitive documents containing the results of its biannual forecasts that it publishes in a normal year, and review arrangements for all other publications,” the report said.
One option would be for the watchdog to use the Government’s digital architecture but publish when it wants.
Another would be to have the Treasury publish the forecasts for the Budget and spring statement, but this would only work if safeguards for “real and perceived independence” could be put in place.
There may need to be an interim solution, the report noted, but said new arrangements must be in place in time for the next statement in spring 2026.
Business
OGRA Announces LPG Price Increase for December – SUCH TV
The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.
According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.
In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.
The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.
-
Sports1 week agoWATCH: Ronaldo scores spectacular bicycle kick
-
Entertainment1 week agoWelcome to Derry’ episode 5 delivers shocking twist
-
Politics1 week agoWashington and Kyiv Stress Any Peace Deal Must Fully Respect Ukraine’s Sovereignty
-
Business1 week agoKey economic data and trends that will shape Rachel Reeves’ Budget
-
Politics1 week ago53,000 Sikhs vote in Ottawa Khalistan Referendum amid Carney-Modi trade talks scrutiny
-
Tech6 days agoWake Up—the Best Black Friday Mattress Sales Are Here
-
Tech1 day agoGet Your Steps In From Your Home Office With This Walking Pad—On Sale This Week
-
Fashion1 week agoCanada’s Lululemon unveils team Canada kit for Milano Cortina 2026
